Akero Therapeutics to Present at Upcoming Healthcare Conferences in May

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) announced its participation in two upcoming investor conferences. The BofA Securities 2022 Healthcare Conference includes a fireside chat on May 11 at 8:40 a.m. PT in Las Vegas, while the H.C. Wainwright Annual Global Life Sciences Conference offers on-demand viewing of a fireside chat on May 24 at 7:00 a.m. ET. Webcasts will be accessible on their website, with archived replays available later. Akero is focused on developing innovative treatments for serious metabolic diseases, particularly NASH.

SOUTH SAN FRANCISCO, May 02, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in the following investor conferences this month:

• BofA Securities 2022 Healthcare Conference: Fireside chat on Wednesday, May 11 at 8:40 a.m. PT. in Las Vegas, Nevada.
• H.C. Wainwright Annual Global Life Sciences Conference: Fireside chat available for on-demand viewing on Tuesday, May 24 at 7:00 a.m. ET.

Webcasts of each Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the webcasts, archived replays will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2/F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Akero is headquartered in South San Francisco. Visit us at www.akerotx.com for more information.

Investor Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com

Media Contact:
650.487.6488
media@akerotx.com

FAQ

What conferences will Akero Therapeutics participate in May 2022?

Akero Therapeutics will participate in the BofA Securities 2022 Healthcare Conference on May 11 and the H.C. Wainwright Annual Global Life Sciences Conference on May 24, 2022.

What is the date and time of Akero's fireside chat at the BofA Securities Conference?

The fireside chat at the BofA Securities Conference is scheduled for May 11, 2022, at 8:40 a.m. PT.

How can I watch the presentations from Akero Therapeutics' investor conferences?

Presentations from Akero Therapeutics' investor conferences can be viewed through the investor relations section of their website, with archived replays available afterwards.

What is the focus of Akero Therapeutics' research?

Akero Therapeutics focuses on developing treatments for serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH), a condition currently without approved therapies.

What is Akero Therapeutics' lead product candidate?

Akero's lead product candidate is efruxifermin (EFX), a potential treatment for NASH designed for convenient once-weekly dosing.